Bicara Therapeutics (BCAX) Interest Expenses (2023 - 2026)

Bicara Therapeutics' Interest Expenses history runs 4 years deep, the most recent figure standing at $108.8 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 108657.0% year-over-year to $108.8 million in Q1 2026; TTM through Mar 2026 was $108.8 million, a 36152.33% increase from a year earlier, with the FY2025 full-year figure at $97.8 million, up 65.68% from the prior year.
• Interest Expenses climbed to $108.8 million in Q1 2026 per BCAX's latest filing, from $100000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $108.8 million in Q1 2026 and bottomed at $8000.0 in Q4 2023.
• The 4-year median for Interest Expenses is $100000.0 (2024), against an average of $16.2 million.
• Across the five-year window, Interest Expenses changed 0.0% in 2025 and soared 108657.0% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $8000.0 in 2023, then jumped by 1150.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then surged by 108657.0% to $108.8 million in 2026.
• Per Business Quant, the three latest BCAX Interest Expenses figures stand at $108.8 million (Q1 2026), $100000.0 (Q4 2025), and $100000.0 (Q3 2025).